Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study

Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia

The drug was recently approved in the US for familial chylomicronaemia syndrome

Ionis reports positive data from study of olezarsen for hypertriglyceridemia

Ionis Pharmaceuticals has reported outcomes from the Phase III Essence study of olezarsen in individuals with moderate hypertriglyceridemia.The post Ionis reports positive data from study of olezarsen for hypertriglyceridemia appeared first on Clinical Trials Arena.

Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study

Olezarsen shows promising results in reducing triglyceride levels for patients with moderate hypertriglyceridemia, offering hope for better cardiovascular health.